SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Isotechnika -- Ignore unavailable to you. Want to Upgrade?

To: teevee who wrote (46)5/22/2003 2:46:53 AM
From: Icebrg  Read Replies (1) | Respond to of 285
 
Yes, it was a very good and informative presentation. I feel more confidence in the drug and the company now.

And the interest for the company is going up. There has been an increase from 7 to 11 boardmarks on the board overnight.

Erik



To: teevee who wrote (46)5/22/2003 3:08:03 PM
From: Biomaven  Read Replies (1) | Respond to of 285
 
IF the drug receives FDA "fast track" approval

I doubt it would qualify for "fast track" - there has to be a serious unmet clinical need. Achieving the same (or even somewhat better) results with less toxicity than an existing drug wouldn't normally qualify you for fast track.

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News